These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12011819)

  • 1. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.
    Mould DR; Holford NH; Schellens JH; Beijnen JH; Hutson PR; Rosing H; ten Bokkel Huinink WW; Rowinsky EK; Schiller JH; Russo M; Ross G
    Clin Pharmacol Ther; 2002 May; 71(5):334-48. PubMed ID: 12011819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism-based models for topotecan-induced neutropenia.
    Léger F; Loos WJ; Bugat R; Mathijssen RH; Goffinet M; Verweij J; Sparreboom A; Chatelut E
    Clin Pharmacol Ther; 2004 Dec; 76(6):567-78. PubMed ID: 15592328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
    Schneider CP; Merkel U; Grübner U; Kath R; Höffken K; Hoffmann A
    J Cancer Res Clin Oncol; 2002 Jun; 128(6):313-8. PubMed ID: 12073049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.
    Loos WJ; Gelderblom H; Sparreboom A; Verweij J; de Jonge MJ
    Clin Cancer Res; 2000 Jul; 6(7):2685-9. PubMed ID: 10914710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
    Latz JE; Chaudhary A; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic model of topotecan-induced time course of neutropenia.
    Zamboni WC; D'Argenio DZ; Stewart CF; MacVittie T; Delauter BJ; Farese AM; Potter DM; Kubat NM; Tubergen D; Egorin MJ
    Clin Cancer Res; 2001 Aug; 7(8):2301-8. PubMed ID: 11489805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
    Boss DS; Siegel-Lakhai WS; van Egmond-Schoemaker NE; Pluim D; Rosing H; Ten Bokkel Huinink WW; Beijnen JH; Schellens JH
    Clin Cancer Res; 2009 Jul; 15(13):4475-83. PubMed ID: 19531625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum cystatin C is a better marker of topotecan clearance than serum creatinine.
    Hoppe A; Séronie-Vivien S; Thomas F; Delord JP; Malard L; Canal P; Chatelut E
    Clin Cancer Res; 2005 Apr; 11(8):3038-44. PubMed ID: 15837759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.
    Armstrong DK; Spriggs D; Levin J; Poulin R; Lane S
    Oncologist; 2005 Oct; 10(9):686-94. PubMed ID: 16249347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors.
    Santana VM; Zamboni WC; Kirstein MN; Tan M; Liu T; Gajjar A; Houghton PJ; Stewart CF
    Clin Cancer Res; 2003 Feb; 9(2):633-40. PubMed ID: 12576429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.
    Curtis KK; Hartney JT; Jewell RC; Park JW; Lebowitz PF; Griffin PP; Borad MJ; Fitch TR; Northfelt DW
    J Clin Pharmacol; 2010 Mar; 50(3):268-75. PubMed ID: 19808951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
    Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
    Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.
    Klein CE; Kastrissios H; Miller AA; Hollis D; Yu D; Rosner GL; Grinblatt DL; Larson RA; Ratain MJ
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):199-206. PubMed ID: 16158312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
    Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topotecan lacks third space sequestration.
    Gelderblom H; Loos WJ; Verweij J; de Jonge MJ; Sparreboom A
    Clin Cancer Res; 2000 Apr; 6(4):1288-92. PubMed ID: 10778953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic analysis of topotecan in pediatric cancer patients.
    Schaiquevich P; Panetta JC; Iacono LC; Freeman BB; Santana VM; Gajjar A; Stewart CF
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6703-11. PubMed ID: 18006771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.